Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer
Published in: Breast Cancer 4/2018

01-07-2018 | Special Feature

The long and winding road for overcoming resistance to hormone therapy in breast cancer

Author: Shigehira Saji

Published in: Breast Cancer | Issue 4/2018

Login to get access

Excerpt

Endocrine therapy is a main modality for hormone receptor (HR)-positive breast cancer. In the treatment of advanced or metastatic HR-positive breast cancer (ABC/MBC), endocrine therapy is generally used as sequential therapy, which uses a single drug one by one when the disease progresses. …
Literature
1.
2.
Saji S, Kimura-Tsuchiya R, Sasaki E. Molecular diagnostics for precision medicine in breast cancer treatment: what does the future hold? Breast Cancer. 2016;23(1):1–3.CrossRefPubMed
3.
4.
Murphy CS, Meisner LF, Wu SQ, Jordan VC. Short- and long-term estrogen deprivation of T47D human breast cancer cells in culture. Eur J Cancer Clin Oncol. 1989;25(12):1777–88.CrossRefPubMed
5.
6.
7.
Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol. 2006;24(11):1770–83.CrossRefPubMed
Metadata
Title
The long and winding road for overcoming resistance to hormone therapy in breast cancer
Author
Shigehira Saji
Publication date
01-07-2018
Publisher
Springer Japan
Published in
Breast Cancer / Issue 4/2018
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-018-0876-2

Other articles of this Issue 4/2018

Breast Cancer 4/2018 Go to the issue

Original Article

OCT4 but not SOX2 expression correlates with worse prognosis in surgical patients with triple-negative breast cancer

Original Article

Meta-analysis for psychological impact of breast reconstruction in patients with breast cancer

Original Article

Clinical utility of RT-PCR in assessing HER 2 gene expression versus traditional IHC and FISH in breast cancer patients

Original Article

Efficacy and safety of trastuzumab, lapatinib, and paclitaxel neoadjuvant treatment with or without prolonged exposure to anti-HER2 therapy, and with or without hormone therapy for HER2-positive primary breast cancer: a randomised, five-arm, multicentre, open-label phase II trial

Special Feature

Clinical development of CDK4/6 inhibitor for breast cancer

Original Article

Preoperative breast MRI: reproducibility and significance of findings relevant to nipple–areolar complex involvement
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits